Form 4: Amphastar Director David Gaugh Receives Equity Compensation

Amphastar Pharmaceuticals Director David Russell Gaugh was granted 6,304 restricted stock units and options to purchase 13,987 shares of common stock as part of his compensation.

Summary

• David Russell Gaugh, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), acquired 6,304 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs were acquired at a price of $0 per share, indicating they are part of compensation.
• The 6,304 RSUs are scheduled to vest on July 18, 2026.
• Mr. Gaugh also acquired options to purchase 13,987 shares of common stock.
• The exercise price for these stock options is $20.62 per share.
• These stock options are scheduled to vest on July 18, 2026, and expire on July 18, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning interests but does not indicate significant new company developments or financial performance.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for retaining and motivating key personnel, including directors.

Future Outlook

The filing indicates future vesting dates for the equity awards on July 18, 2026, aligning the director's long-term interest with the company's performance.

Industry Context

The grant of equity awards to a director is a common practice across various industries, particularly in the pharmaceutical sector, to incentivize long-term commitment and align management interests with shareholder value.

Related Party Transactions

• The filing discloses the acquisition of 6,304 restricted stock units and options for 13,987 shares by David Russell Gaugh, a Director of Amphastar Pharmaceuticals, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholder value creation, as the value of the awards is tied to the company's stock performance.
• Employees: While not directly impacting all employees, this type of compensation structure for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The restricted stock units and stock options are scheduled to vest on July 18, 2026.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Director, Equity Compensation, Restricted Stock Units, RSU, Stock Options, Insider Transaction, Compensation